Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

VALORISATION AND OPTIMIZATION OF NOVEL FIRST-IN CLASS SUCCINATE-DEPLETING THERAPIES

Objetivo

SUCCIPRO is a spin-off company from Pere Virgili Health Institute and Rovira Virgili University. It is an early-stage drug development company focused on therapies able to modulate the succinate-SUCNR1 pathway, which have strong potential on many inflammatory and metabolic disorders. Currently, the company is developing SUCZYME, a novel first-in-class oral enzyme therapy able to deplete succinate that has Crohn's Disease as a first indication. SUCCIPRO will lead the development until the end of Clinical Phase 2a, when the asset will be licensed to a bigger pharma company.
Current proposal aims to conduct critical technical and business activities with the overall goal of raising a first seed investment round. From a technological perspective, during the project the team will advance in the development of the enzyme therapy by partnering with an innovative company expert in enzyme engineering able to improve our candidates in terms of specificity, activity and stability. Later, we will conduct in vitro and in vivo efficacy studies that will enable the designation of final lead candidate. In parallel to the technical development, and in order to have more a more accurate vision about the European market, we aim to perform early price & reimbursement and market studies in Europe. We will also participate in the activities organised by InvestEU and the Enterprise Europe Network and we will introduce our company into the US start-up ecosystem to expand company's innovation network and look for investment in the US. Overall, the project will contribute to increase the TRL level of our asset, improve our competitiveness and visibility within the international biotech sector and support us in the raising of a seed investment round.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véase: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

Para utilizar esta función, debe iniciar sesión o registrarse

Régimen de financiación

HORIZON-CSA -

Coordinador

SUCCIPRO SL
Aportación neta de la UEn
€ 75 000,00
Dirección
CALLE DEMOCRACIA 22 CASA B
08018 Barcelona
España

Ver en el mapa

Pyme

Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.

Región
Este Cataluña Barcelona
Tipo de actividad
Entidades privadas con ánimo de lucro (excluidos los institutos de educación secundaria o superior)
Enlaces
Coste total
Sin datos
Mi folleto 0 0